BR112015008612A2 - métodos de tratamento utilizando adenovirus - Google Patents

métodos de tratamento utilizando adenovirus

Info

Publication number
BR112015008612A2
BR112015008612A2 BR112015008612A BR112015008612A BR112015008612A2 BR 112015008612 A2 BR112015008612 A2 BR 112015008612A2 BR 112015008612 A BR112015008612 A BR 112015008612A BR 112015008612 A BR112015008612 A BR 112015008612A BR 112015008612 A2 BR112015008612 A2 BR 112015008612A2
Authority
BR
Brazil
Prior art keywords
adenovirus
tumor
decreasing
treatment methods
operably linked
Prior art date
Application number
BR112015008612A
Other languages
English (en)
Inventor
Leubitz Andrea
Feige Erez
Breitbart Eyal
Penson Richard
Original Assignee
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Biogenics Ltd filed Critical Vascular Biogenics Ltd
Publication of BR112015008612A2 publication Critical patent/BR112015008612A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo “métodos de tratamento utilizando adenovirus” a invenção fornece métodos para reduzir ou diminuir o tamanho de um tumor ou eliminar um tumor, ou inibir, diminuir, ou reduzir a neovascularização ou angiogênese num tumor em um paciente, através da administração de um adenovírus compreendendo um construto de ácido nucleico compreendendo um gene fas quimérico operativamente ligado a um promotor específico de células endoteliais. também é fornecida uma população homogênea de um adenovírus compreendendo um gene fas quimérico operativamente ligado a um promotor específico de células endoteliais e as utilizações da mesma.
BR112015008612A 2012-10-17 2013-10-17 métodos de tratamento utilizando adenovirus BR112015008612A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261715206P 2012-10-17 2012-10-17
US201361785287P 2013-03-14 2013-03-14
PCT/IB2013/003015 WO2014060848A2 (en) 2012-10-17 2013-10-17 Treatment methods using adenovirus

Publications (1)

Publication Number Publication Date
BR112015008612A2 true BR112015008612A2 (pt) 2017-09-26

Family

ID=50488836

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015008612A BR112015008612A2 (pt) 2012-10-17 2013-10-17 métodos de tratamento utilizando adenovirus

Country Status (26)

Country Link
US (4) US9200056B2 (pt)
EP (2) EP2908865B1 (pt)
JP (2) JP6336459B2 (pt)
KR (2) KR102229084B1 (pt)
CN (2) CN105025931B (pt)
AU (3) AU2013333571B2 (pt)
BR (1) BR112015008612A2 (pt)
CA (1) CA2888193A1 (pt)
CY (1) CY1121185T1 (pt)
DK (1) DK2908865T3 (pt)
EA (1) EA034163B1 (pt)
ES (1) ES2703913T3 (pt)
HK (1) HK1208625A1 (pt)
HR (1) HRP20182125T1 (pt)
HU (1) HUE042262T2 (pt)
IL (2) IL238313B (pt)
LT (1) LT2908865T (pt)
MX (2) MX366163B (pt)
NZ (1) NZ707336A (pt)
PL (1) PL2908865T3 (pt)
PT (1) PT2908865T (pt)
RS (1) RS58122B1 (pt)
SG (2) SG10201706485WA (pt)
SI (1) SI2908865T1 (pt)
WO (1) WO2014060848A2 (pt)
ZA (1) ZA201502712B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011083464A2 (en) 2010-01-05 2011-07-14 Vascular Biogenics Ltd. Methods for use of a specific anti-angiogenic adenoviral agent
US20130209450A1 (en) 2010-01-05 2013-08-15 Yael Cohen Compositions and Methods for Treating Glioblastoma GBM
CA2888193A1 (en) 2012-10-17 2014-04-24 Eyal Breitbart Treatment methods using adenovirus
US9682154B2 (en) 2013-02-04 2017-06-20 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
NZ725303A (en) * 2014-04-04 2019-02-22 Taiho Pharmaceutical Co Ltd Anti-tumor agent containing taxane compound, and anti-tumor effect enhancer
US10189887B2 (en) 2014-04-17 2019-01-29 Inserm (Institut National De La Sante Et De La Recherche Medicale) Polypeptides and uses thereof for reducing CD95-mediated cell motility
FI127460B (en) * 2016-01-15 2018-06-29 Targovax Oy COMBINATION OF ADENOVIRUS AND CHEMOTHERAPY AGENTS FOR CANCER CARE
CA3048313A1 (en) * 2017-01-06 2018-07-12 Stabilitech Biopharma Ltd Virus
CN111356480A (zh) * 2017-10-20 2020-06-30 脉管生物生长有限公司 用于抗血管生成剂疗法的诊断方法
CN113677351A (zh) * 2018-12-20 2021-11-19 芝加哥大学 与用于癌症疗法的治疗肽相关的方法和组合物
EP3937959A1 (en) * 2019-03-13 2022-01-19 Vascular Biogenics Ltd. Methods of anti-tumor therapy
WO2020208612A1 (en) * 2019-04-12 2020-10-15 Vascular Biogenics Ltd. Methods of anti-tumor therapy
WO2021194183A1 (ko) * 2020-03-25 2021-09-30 ㈜큐리진 면역 회피성 항종양 아데노바이러스
WO2022056488A1 (en) * 2020-09-14 2022-03-17 Genprex, Inc. Nonviral vectors for increasing fas expression in cancer cells and methods of use thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3773319A (en) 1971-12-16 1973-11-20 Fabcor Ind Inc Corrugated sheet inverting machine
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
UA70909C2 (uk) 1993-10-25 2004-11-15 Канджи Інк. Рекомбінантний аденовірусний вектор, фармацевтична композиція, що його містить, та набір для зменшення проліферації пухлинних клітин
WO1995011984A2 (en) 1993-10-25 1995-05-04 Canji, Inc. Recombinant adenoviral vector and methods of use
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
US20070286845A1 (en) 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8039261B2 (en) 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US7067649B2 (en) 2000-11-17 2006-06-27 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20100282634A1 (en) 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
CN1294268C (zh) 2001-09-03 2007-01-10 上海三维生物技术有限公司 可在肿瘤细胞内特异性复制并扩散的重组腺病毒载体
EP2277887A3 (en) 2001-10-19 2011-02-16 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
KR20070044868A (ko) 2005-10-26 2007-05-02 주식회사 바이오인프라 스트렙토라이신 ｏ 단백질을 암호화하는 유전자를 발현하는재조합 아데노바이러스 및 이를 유효성분으로 하는 항암용조성물
CA2658972C (en) 2006-07-31 2019-11-26 Vascular Biogenics Ltd. Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia
WO2008074189A1 (fr) 2006-12-20 2008-06-26 Shenzhen Well.D Genetic Engineering Co., Ltd Adénovirus recombinant comprenant un gène khp50 recombinant et son procédé de préparation et ses utilisations
CN101348512B (zh) 2007-07-20 2012-08-15 郑州威瑞生物技术有限公司 一种抗肿瘤的腺病毒制剂
JP4896102B2 (ja) 2008-09-12 2012-03-14 富士フイルム株式会社 レンズ装置
KR101248912B1 (ko) 2009-12-31 2013-03-29 한양대학교 산학협력단 항혈관신생 활성을 가지는 재조합 아데노바이러스
US20130209450A1 (en) 2010-01-05 2013-08-15 Yael Cohen Compositions and Methods for Treating Glioblastoma GBM
WO2011083464A2 (en) 2010-01-05 2011-07-14 Vascular Biogenics Ltd. Methods for use of a specific anti-angiogenic adenoviral agent
JP6009357B2 (ja) * 2010-01-12 2016-10-19 バスキュラー バイオジェニックス リミテッド アデノウイルスベクターの生産方法およびそれによって生成されるウイルス調製物
KR101253276B1 (ko) 2010-07-27 2013-04-10 윤채옥 복합 유전자 치료용 항종양 조성물
KR101232123B1 (ko) 2010-10-08 2013-02-12 연세대학교 산학협력단 재조합된 유전자발현 조절서열을 가지는 종양 특이적 발현이 개선된 유전자 전달체
EP2630186A1 (en) 2010-10-18 2013-08-28 Total Research & Technology Feluy Expandable vinyl aromatic polymers
WO2012052878A1 (en) 2010-10-19 2012-04-26 Vascular Biogenics Ltd. Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells
CA2888193A1 (en) * 2012-10-17 2014-04-24 Eyal Breitbart Treatment methods using adenovirus
US9682154B2 (en) 2013-02-04 2017-06-20 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent

Also Published As

Publication number Publication date
KR20150068978A (ko) 2015-06-22
EP2908865A2 (en) 2015-08-26
KR20190067279A (ko) 2019-06-14
WO2014060848A2 (en) 2014-04-24
AU2013333571A1 (en) 2015-05-14
CA2888193A1 (en) 2014-04-24
MX366163B (es) 2019-07-01
AU2018271398A1 (en) 2018-12-20
JP2018140999A (ja) 2018-09-13
AU2018271398B2 (en) 2020-11-05
KR102229084B1 (ko) 2021-03-18
KR101989171B1 (ko) 2019-06-14
HRP20182125T1 (hr) 2019-02-08
HUE042262T2 (hu) 2019-06-28
SG10201706485WA (en) 2017-09-28
RS58122B1 (sr) 2019-02-28
JP6630397B2 (ja) 2020-01-15
SG11201502941VA (en) 2015-05-28
US11311583B2 (en) 2022-04-26
DK2908865T3 (en) 2019-01-28
EP3441089B1 (en) 2022-12-14
IL238313B (en) 2020-07-30
EA201590747A1 (ru) 2015-10-30
HK1208625A1 (en) 2016-03-11
ES2703913T3 (es) 2019-03-13
CN105025931B (zh) 2017-04-05
JP6336459B2 (ja) 2018-06-06
US20150044280A1 (en) 2015-02-12
SI2908865T1 (sl) 2019-02-28
US9200056B2 (en) 2015-12-01
US20160143968A1 (en) 2016-05-26
EP2908865B1 (en) 2018-10-03
IL275874A (en) 2020-08-31
EP2908865A4 (en) 2016-05-25
JP2015536318A (ja) 2015-12-21
ZA201502712B (en) 2016-07-27
MX2019007057A (es) 2019-08-29
EA034163B1 (ru) 2020-01-13
AU2013333571B2 (en) 2017-01-19
CN105025931A (zh) 2015-11-04
AU2017202492A1 (en) 2017-05-04
EP3441089A1 (en) 2019-02-13
PL2908865T3 (pl) 2019-08-30
AU2017202492B2 (en) 2018-09-06
IL238313A0 (en) 2015-06-30
LT2908865T (lt) 2019-01-10
NZ707336A (en) 2019-01-25
CY1121185T1 (el) 2020-05-29
WO2014060848A3 (en) 2014-11-27
US20220331383A1 (en) 2022-10-20
MX2015004835A (es) 2015-08-20
CN107096041A (zh) 2017-08-29
US20190054130A1 (en) 2019-02-21
PT2908865T (pt) 2019-01-11

Similar Documents

Publication Publication Date Title
BR112015008612A2 (pt) métodos de tratamento utilizando adenovirus
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
PH12015500825B1 (en) Substituted benzene compounds
MX2013011922A (es) Compuestos de benceno substituido.
MX2020010535A (es) Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide.
PH12014501702A1 (en) Imidazopyrrolidinone compounds
MX2020012695A (es) Compuestos de benceno substituidos con arilo o heteroarilo.
MX2015006234A (es) Uso de akkermansia para tratar trastornos metabolicos.
MX343043B (es) Promotores de apoptosis de n-acilsulfonamida.
WO2013169864A3 (en) TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
MX369803B (es) Derivados de acilaminopirimidina para el tratamiento de infecciones viricas y otras enfermedades.
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
EA201300592A1 (ru) Ингибиторы апоптоза и их применение
BR112015021265A2 (pt) métodos de aperfeiçoamento de uso para secretoglobinas humanas recombinantes
NZ704554A (en) Combination therapy of a smac mimetic and gm-csf
MX2014014839A (es) Terapias sinergicas de cannabidiol con hipotermia para neuroproteccion.
EA201992441A1 (ru) Способы лечения с использованием аденовируса
GB2519004A (en) Quinone compounds and their uses for the treatment of cancer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]